Welcome to our dedicated page for Aditxt SEC filings (Ticker: ADTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aditxt, Inc. filings document the company’s life sciences platform, its common stock capital structure, and material events affecting its operating subsidiaries and public-company status. Recent Form 8-K reports cover the completed acquisition of Ignite Proteomics, related financial statements and pro forma information, senior unsecured promissory notes, at-the-market offering capacity, and Nasdaq listing-compliance matters.
Proxy materials and meeting reports describe board elections, auditor ratification, executive-compensation votes, reverse stock split authority, and other stockholder matters. The filing record also includes disclosures on preferred stock issued in acquisition consideration, equity financing arrangements, governance approvals, and risks associated with maintaining exchange listing standards.
Aditxt, Inc. registers up to 148,278,241 shares of Common Stock for resale by selling stockholders, representing shares issuable upon exercise of outstanding warrants. The registration covers resale on a resale basis by the identified selling holders.
The Company will not receive proceeds from secondary sales; however, if the warrants are exercised for cash at the current $0.50 exercise price, cash proceeds to the Company would be approximately $74.14 million. The prospectus states the company’s Nasdaq closing price on April 2, 2026 was $0.794 per share.
Aditxt, Inc. filed an amended current report to add full financial statements for its acquisition of Ignite Proteomics LLC and related unaudited pro forma consolidated financials. The deal consideration includes 36,000 shares of Series A-2 Convertible Preferred Stock with an aggregate stated value of $36.0 million.
Ignite’s audited results show modest 2025 revenue of $43,539 and a net loss of $5,701,059, leading to a member’s deficit of $6,807,109 and a going concern warning due to recurring losses and negative operating cash flows. Pro forma balance sheets record preliminary goodwill of $36,551 (in thousands of dollars) related to the transaction.
Aditxt, Inc. is calling a virtual 2026 annual meeting on May 1, 2026 at 12:00 p.m. ET, where holders of common stock as of the March 26, 2026 record date, when 861,482 shares were outstanding, can vote online.
Stockholders will vote on six items: electing five directors for one-year terms; ratifying dbbmckennon as independent auditor for 2026; an advisory “say‑on‑pay” vote on executive compensation; an advisory vote on how often to hold say‑on‑pay, with the board recommending every three years; authorizing the board to implement a reverse stock split within one year at a ratio between 1‑for‑2 and 1‑for‑250; and approving the ability to adjourn the meeting if needed.
The proxy details leadership and compensation, including 2025 base salaries of $500,000 for CEO Amro Albanna, $325,000 for Chief Innovation Officer Shahrokh Shabahang, $385,008 for Chief M&A Officer Corinne Pankovcin, and $395,000 for CFO Thomas Farley, plus change‑in‑control severance protections. It also confirms independent board committees, audit fees, and that the reverse split is intended to support Nasdaq listing and broaden investor appeal.
Aditxt, Inc. reports that Nasdaq has determined the company is back in compliance with its continued listing standards under Nasdaq Listing Rule 5550(b)(1). This decision is based on Aditxt’s Form 10-K, which shows stockholders’ equity of $3,953,682, and Nasdaq has closed the matter.
Aditxt, Inc. files its annual report describing a multi-subsidiary biotech platform focused on immune modulation, molecular diagnostics and infectious disease therapeutics, all still in development with no significant commercial revenue. The company reports a net loss of $42,787,043 for 2025 and an accumulated deficit of $209,808,770, raising substantial doubt about its ability to continue as a going concern.
Aditxt highlights Adimune’s ADI-100 immune tolerance candidate moving toward first-in-human trials, Pearsanta’s Mitomic-based cancer and endometriosis tests in development, and newer platforms in antiviral (Adivir) and women’s health (Adifem). The company outlines the now-terminated Evofem merger after multiple amendments, while retaining its Evofem preferred shares and warrants.
The report flags serious Nasdaq listing risks. As of March 30, 2026, Aditxt’s market capitalization is about $713,000, far below both existing equity thresholds and a proposed $5.0M market cap standard that, if adopted, could trigger rapid suspension and delisting without a cure period. Aditxt states its current cash will not fund 12 months of operations and that it must raise additional capital, with uncertainty around availability and terms.
Aditxt, Inc. increased the maximum aggregate offering price of its at-the-market common stock program to $53,398,964 under its Sales Agreement with H.C. Wainwright & Co.
This includes an additional $36,800,000 of capacity, on top of approximately $21,257,000 of common stock already sold under the agreement, and is supported by a new prospectus supplement and related legal opinion filed as an exhibit.
ADTX amends its shelf to increase its ATM capacity to $53,398,964. This prospectus supplement adds $36,800,000 of new ATM capacity, bringing the aggregate authorized amount under the sales agreement to $53,398,964, and leaves prior terms and the sales agreement unchanged.
The supplement states the company has previously sold approximately 398,950 shares for aggregate gross proceeds of $21,257,000, leaving about $16,500,000 of prior capacity before this increase. The filing also discloses the last reported Nasdaq sale price of the common stock was $0.81 per share as of March 27, 2026.
Aditxt, Inc. is soliciting proxies for its 2026 Annual Meeting to be held in a virtual-only format at www.virtualshareholdermeeting.com/ADTX2026. Stockholders of record as of the board‑fixed [RECORD DATE], 2026 may vote on six proposals.
The six proposals include: (1) election of five director nominees (the board will be reduced to five following the meeting), (2) ratification of dbbmckennon as auditor, (3) an advisory "say-on-pay" vote, (4) an advisory vote on say-on-pay frequency (the board recommends EVERY 3 YEARS), (5) authorization to permit the board to effect a reverse stock split within one year at a ratio the board may set within a disclosed range, and (6) authorization to adjourn the meeting if needed. The proxy materials and the 2025 Annual Report on Form 10-K are available at www.proxyvote.com.
Aditxt, Inc. entered into a definitive agreement to acquire Ignite Proteomics, LLC, obtaining 100% of Ignite’s equity plus $475,000 in cash in exchange for 36,000 shares of newly created Series A-2 Convertible Preferred Stock with an aggregate stated value of $36,000,000.
The preferred shares convert into common stock at a Conversion Price of $2.731 per share, subject to adjustments and a 9.99% beneficial ownership cap, and may be redeemed by Aditxt at 100% of the conversion amount. On March 11, 2026, Aditxt also issued 10% original issue discount promissory notes with aggregate principal of $3,194,444.44, providing $2,875,000 in funding at 6% annual interest (rising to 12% on default) and maturing nine months after issuance.
The company believes the Ignite transaction has increased its stockholders’ equity above $2.5 million, which would bring it back into compliance with Nasdaq’s stockholders’ equity listing requirement, and is awaiting Nasdaq’s formal confirmation.
Aditxt, Inc. is implementing a 1-for-8 reverse stock split of its common stock to address Nasdaq’s minimum bid price requirement. The company filed a certificate of amendment in Delaware, with the split effective at 4:01 p.m. Eastern Time on March 6, 2026.
Beginning when Nasdaq opens on March 9, 2026, Aditxt’s shares will trade on a split-adjusted basis under the existing symbol ADTX with a new CUSIP number 007025877. Every 8 issued and outstanding common shares will be combined into 1 share, with fractional shares rounded up.
Immediately after the reverse split becomes effective, Aditxt expects to have approximately 517,856 shares of common stock outstanding. Outstanding stock options, restricted stock units, and warrants, as well as plan reserves, will be proportionately adjusted in both share count and exercise price.